Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Era in Breast Cancer Treatment with Immunotherapy

A New Era in Breast Cancer Treatment with Immunotherapy

A new era in breast cancer treatment

In early-stage, hormone receptor-positive and HER2 -negative breast cancer, neoadjuvant (preoperative tumor-shrinking) treatment with pembrolizumab (Keytruda) immunotherapy added has been shown to significantly increase pathological complete response rates.

As reported by Dr. Rita Nanda and colleagues in JAMA Oncology , findings from the ongoing phase II I-SPY 2 trial showed that adding pembrolizumab to standard neoadjuvant chemotherapy significantly improved pathological complete response rates in high-risk stage 2 and 3 breast cancer patients.

What Are the Study's Noteworthy Findings?

  • Among all patients, pathological complete response rates were % 44 in the chemotherapy plus pembrolizumab group and % 17 in the control group receiving chemotherapy alone.
  • Triple-negative breast cancer patients had pathological complete response rates of % 60 versus % 22 in the pembrolizumab and control groups.
  • In the hormone-positive / HER2-negative group, pathological complete response rates were %30 versus %13.

What Is a Pathological Complete Response?

A pathological complete responseis a pathology result showing how effective the treatment given before surgery has been. If no cancer cells are found in the surgical pathology examination after neoadjuvant treatment, this is called a pathological complete response. Many studies have demonstrated that patients who achieve a pathological complete response have a lower likelihood of cancer recurrence.

breast cancer types breast cancer treatment

Study Details

The I-SPY 2 clinical trialis an open-label, multicenter, adaptively randomized phase II platform trial evaluating the addition of pembrolizumab immunotherapy to standard taxane- and anthracycline-based neoadjuvant chemotherapy. Risk scores of enrolled patients with stage 2 and 3 breast cancer were determined using MammaPrint and TargetPrint ERBB2 tests. Patients in the MammaPrint low-risk group were excluded from I-SPY 2 because more intensive treatment was not required.

- Related topic: How do we identify patients who will not receive chemotherapy after breast cancer surgery?

Within the study, between 2015 – 2016, HER2 test-negative 181 patients with breast cancer were randomly assigned to standard neoadjuvant chemotherapy (weekly paclitaxel followed by doxorubicin + cyclophosphamide); 69 patients were assigned to chemotherapy plus pembrolizumab. Pembrolizumab immunotherapy was given for 4 cycles. Patients in both groups then underwent breast cancer surgery . In the pembrolizumab group, 40 patients had hormone receptor-positive and 29 had triple-negative breast cancer.

Pathological Complete Response Rates

Final estimated pathological complete response rates among all HER2-negative patients were % 44 versus % 17 for pembrolizumab and the control group, respectively. Among patients with triple-negative breast cancer, the rates for pembrolizumab and the control group were % 60 versus % 22. In the hormone-positive / HER2-negative group, pathological complete response rates were %30 versus %13.

In other words, for all subgroups, adding pembrolizumab immunotherapy to chemotherapy significantly reduced the likelihood of residual disease being found at surgery. Median follow-up was 2.8 years in the pembrolizumab group and 3.5 years in the control group. Another analysis showed no significant difference between groups in 3-year event-free survival. Researchers noted that patients with a pathological complete response in both groups had excellent 3-year event-free survival rates (for example, % 93 in the pembrolizumab group).

What Adverse Effects Were Observed?

Adverse effects were consistent with the previously known safety profiles of the cancer treatments in both groups. As expected, immunotherapy-related adverse effects were more common in the pembrolizumab group. The most common were endocrinopathies: thyroid dysfunction (hypothyroidism and hyperthyroidism), which occurred in % 13 of patients. Adrenal insufficiency (failure of the adrenal glands) was observed in % 8.7 of patients; five of the six reported cases of this adverse effect occurred 30 days after the last pembrolizumab dose. Other immune-related adverse effects, except itching, were observed to occur 30 days after the last pembrolizumab dose.

Conclusion

When added to standard neoadjuvant chemotherapy, pembrolizumab immunotherapy doubled pathological complete response rates in stage 2 and 3 hormone-positive / HER2-negative and triple-negative breast cancer. 

Related Topic:

- Life expectancy estimates given to patients with stage 4 breast cancer are rarely accurate

Sources

Rita Nanda, Minetta C. Liu, Christina Yau et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA Oncol. 13 Feb 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Era in Breast Cancer Treatment with Immunotherapy

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy